OmniAb Q2 revenue $7.6M, net loss $0.13/sh; guides 2024 opex slightly below 2023

OmniAb, Inc.

2024-Q2 EPS reported -$0.32 revenue$11,415,000

Q2 2024 revenue $7.6M (+10% YoY), net loss $13.6M ($0.13/sh) vs $14.7M loss in Q2 2023.
H1 2024 revenue $11.4M vs $23.9M (prior year included $10M TECVAYLI milestone); net loss $32.6M ($0.32/sh).
Cash $57.2M at June 30; expects 2024 opex slightly below 2023, cash use similar to 2023 ex-$35M milestone.
New platform licenses with DAAN Bio, Topaz Therapeutics, HanAll Biopharma; post-Q2 deals with 92Bio and Memorial Sloan Kettering.
GSK discontinued Nav1.1 program (OmniAb retains co-ownership); Roche returning Kv7.2 rights (not due to scientific reasons).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.